The management of "slow-go" patients with chronic lymphocytic leukemia (CLL) remains a primary unmet clinical need. This subgroup of patients, underrepresented in clinical trials, represents the burden of patients with CLL that will progressively increase in future years. Diagnostic tools to identify this patient population are emerging: the Cumulative Illness Rating Scale and reproducible geriatric functionality tests should be included, in addition to the traditional performance status assessment, in the work-up of elderly patients prior to treatment, in order to use a common language and better focus the aims of therapy. Quality of life has to be preserved and evaluated with dedicated tests. Evidence-based therapeutic strategies for "slow-go" patients with CLL are still lacking. Therefore, monotherapy with chlorambucil ± rituximab and possibly fludarabine or bendamustine remains a first-line option outside clinical trials. Bendamustine + rituximab, pentostatin+rituximab±cyclophosphamide, fludarabine + cyclophosphamide at reduced doses, and chlorambucil plus new anti-CD20 antibodies can be options to be assessed within clinical trials, as their claimed acceptable toxicity is formally unproven. Clinical trials specifically designed for "slow-go" CLL are strongly needed, and the enrollment of patients in dedicated trials is recommended. New non-chemotherapeutic drugs could be also explored in this setting.

Chronic lymphocytic leukemia in less fit patients: "slow-go" / DEL GIUDICE, Ilaria; Mauro, Francesca Romana; Foa, Roberto. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 52:12(2011), pp. 2207-2216. [10.3109/10428194.2011.606386]

Chronic lymphocytic leukemia in less fit patients: "slow-go".

DEL GIUDICE, ILARIA;MAURO, Francesca Romana;FOA, Roberto
2011

Abstract

The management of "slow-go" patients with chronic lymphocytic leukemia (CLL) remains a primary unmet clinical need. This subgroup of patients, underrepresented in clinical trials, represents the burden of patients with CLL that will progressively increase in future years. Diagnostic tools to identify this patient population are emerging: the Cumulative Illness Rating Scale and reproducible geriatric functionality tests should be included, in addition to the traditional performance status assessment, in the work-up of elderly patients prior to treatment, in order to use a common language and better focus the aims of therapy. Quality of life has to be preserved and evaluated with dedicated tests. Evidence-based therapeutic strategies for "slow-go" patients with CLL are still lacking. Therefore, monotherapy with chlorambucil ± rituximab and possibly fludarabine or bendamustine remains a first-line option outside clinical trials. Bendamustine + rituximab, pentostatin+rituximab±cyclophosphamide, fludarabine + cyclophosphamide at reduced doses, and chlorambucil plus new anti-CD20 antibodies can be options to be assessed within clinical trials, as their claimed acceptable toxicity is formally unproven. Clinical trials specifically designed for "slow-go" CLL are strongly needed, and the enrollment of patients in dedicated trials is recommended. New non-chemotherapeutic drugs could be also explored in this setting.
2011
01 Pubblicazione su rivista::01a Articolo in rivista
Chronic lymphocytic leukemia in less fit patients: "slow-go" / DEL GIUDICE, Ilaria; Mauro, Francesca Romana; Foa, Roberto. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 52:12(2011), pp. 2207-2216. [10.3109/10428194.2011.606386]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/417689
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 13
social impact